secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0001171843-23-004458
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus appoints Melissa V. Rewolinski, PhD to its board of directors
---------------------------------------------------------------------

- Melissa V. Rewolinski appointed to board effective July 12, 2023; board expands to seven members.
- She joins Compensation Committee; receives $40,000 annual retainer plus $7,500 for committee service.
- Granted option for 110,000 common shares vesting over 3 years; exercise price based on July 12 closing price.
- Dr. Rewolinski brings 20+ years pharma experience; previously at Intercept, Amira, Pfizer; currently MVR Consulting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004458/0001171843-23-004458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004458/f8k_071223.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer